MacroGenics Q4 2025 EPS -$0.23 on revenue $41.2M, misses EPS, beats revenue, affirms cash runway
MacroGenics posts Q4 2025 EPS -$0.23 on revenue $41.2M, misses EPS, beats revenue, affirms cash runway into late 2027
- Q4 2025 non-GAAP EPS -$0.23 rose 4% YoY, revenue $41.2M grew 113% YoY and beat estimates.
- Provides 2026 timelines for initial MGC026 and MGC028 Phase 1 data.
- Provides a mid‑2026 LINNET lorigerlimab update timeline as part of its 2026 timelines.
- Plans a 3Q 2026 IND filing for MGC030 according to its 2026 timelines disclosure.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.